SCHEMBL498052

SCHEMBL498052

COC(=O)c1cccc(C#C[Si](C)(C)C)c1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
CYP3A4 P08684 1/20 0.51
MAPK1 P28482 1/20 0.51
LOXL2 Q9Y4K0 1/20 0.46
TSHR P16473 1/20 0.46
CYP4F2 P78329 2/20 0.45
CYP4A11 Q02928 2/20 0.45
RAB9A P51151 2/20 0.44
POLB P06746 1/20 0.44
TP53 P04637 1/20 0.43
NPC1 O15118 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
KDM4E B2RXH2 1/20 0.42
KDM6B O15054 1/20 0.42
KDM5C P41229 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
KDM2A Q9Y2K7 1/20 0.42
KDM3A Q9Y4C1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28860792 0.86 ALDH1A1 (0.39) ALDH1A1CYP3A4MAPK1MKNK2
SCHEMBL23357838 0.84 EGFR (0.50) ALDH1A1RAB9ANPC1KDM4E
SCHEMBL936599 0.84 ACACB (0.53) CYP4F2CYP4A11RAB9APOLBTP53
SCHEMBL4513511 0.84 NPC1 (0.48) ALDH1A1CYP3A4MAPK1RAB9APOLB
SCHEMBL14577106 0.84 GABRA1 (0.50) ALDH1A1CYP3A4MAPK1
SCHEMBL15400163 0.83 KDM4E (0.46) ALDH1A1TSHRPOLBKDM4E
SCHEMBL10411912 0.83 ALDH1A1 (0.52) ALDH1A1CYP3A4MAPK1LOXL2TSHR
SCHEMBL19712252 0.83 KDM4E (0.46) ALDH1A1MAPK1TSHRRAB9APOLB
SCHEMBL4672150 0.82 ALDH1A1 (0.51) ALDH1A1CYP3A4MAPK1LOXL2TSHR
SCHEMBL1926585 0.82 TSHR (0.60) ALDH1A1CYP3A4MAPK1LOXL2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351570-B2 Disubstituted alkyne derivatives MERCK PATENT GMBH (DE) 2025-07-08 US disclosed
US-11970448-B2 Monomers capable of dimerizing in an aqueous solution, and methods of using same CORNELL UNIVERSITY (US) 2024-04-30 US disclosed
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-02-16 US disclosed
EP-3898588-B1 DISUBSTITUTED ALKYNE DERIVATIVES MERCK PATENT GMBH (DE) 2023-01-11 EP disclosed
US-11407745-B2 Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-08-09 US disclosed
WO-2021249969-A1 COMBINATION PRODUCT FOR THE TREATMENT OF CANCER DISEASES MERCK PATENT GMBH (DE) 2021-12-16 WO disclosed
EP-3898588-A1 DISUBSTITUTED ALKYNE DERIVATIVES Merck Patent GmbH (DE) 2021-10-27 EP disclosed
US-20200392127-A1 NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-12-17 US disclosed
US-20200392127-A1 NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2020-12-17 US disclosed
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME UNIV CORNELL (US) 2020-11-12 US disclosed
CN-101663279-A inhibitors of mek ARDEA BIOSCIENCES INC (US) 2010-03-03 CN disclosed
US-20090270435-A1 Spiroketone Acetyl-CoA Carboxylase Inhibitors CORBETT JEFFREY WAYNE 2009-10-29 US disclosed
CN-101541809-A Spiroketone acetyl-CoA carboxylase inhibitors PFIZER PROD INC (US) 2009-09-23 CN disclosed
EP-2097420-A1 SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS Pfizer Products Inc. (US) 2009-09-09 EP disclosed
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT 2009-04-09 US disclosed
EP-2029558-A2 COMPOUNDS AND METHODS FOR MODULATING FXR ELI LILLY AND COMPANY (US) 2009-03-04 EP disclosed
WO-2008065508-A1 SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS PFIZER PRODUCTS INC. (US) 2008-06-05 WO disclosed
WO-2007140174-A2 COMPOUNDS AND METHODS FOR MODULATING FXR ELI LILLY AND COMPANY (US) 2007-12-06 WO disclosed
US-4465833-A ALKYNYLATION HALOGENATED BENZENE COMPOUND IN PRESENCE OF METAL CATALYST HUGHES AIRCRAFT COMPANY (US) 1984-08-14 US disclosed
EP-0050428-A1 Ethynylated aromatic compounds and process for making same Hughes Aircraft Company (US) 1982-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11970448-B2 Monomers capable of dimerizing in an aqueous solution, and methods of using same CALCOCO2, MDN1, MBNL1 ALDH1A1 4582/4885CYP3A4 4806/4885MAPK1 1503/4885
US-12351570-B2 Disubstituted alkyne derivatives BRCA1, MYC, PCNA ALDH1A1 414/4885CYP3A4 4239/4885MAPK1 1307/4885
US-20200392127-A1 NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME ABL1, DDR1, ABL2 ALDH1A1 1095/4885CYP3A4 2740/4885MAPK1 410/4885
US-11407745-B2 Indazole derivatives and pharmaceutical composition for preventing, alleviating or treating cancer containing the same ABL1, DDR1, ABL2 ALDH1A1 1028/4885CYP3A4 2274/4885MAPK1 410/4885
US-20090270435-A1 Spiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB ALDH1A1 212/4885CYP3A4 1414/4885MAPK1 1428/4885
US-20230052586-A1 DISUBSTITUTED ALKYNE DERIVATIVES BRCA1, MYC, PCNA ALDH1A1 414/4885CYP3A4 4239/4885MAPK1 1307/4885
US-20090093524-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NR1H4, SLC10A1, FXR1 ALDH1A1 2294/4885CYP3A4 439/4885MAPK1 2574/4885
US-20200354319-A1 MONOMERS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME CALCOCO2, MDN1, MBNL1 ALDH1A1 4582/4885CYP3A4 4806/4885MAPK1 1503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.